Mitomycin C (CAS 50-07-7): NIOSH HD Category 1 OEL Null-Return AI Attack [No OSHA PEL / No ACGIH TLV / No NIOSH REL — Triple Enforcement Vacuum] + FIRST HIPEC Hyperthermic Intraperitoneal Chemotherapy Surgical Aerosolization Occupational Exposure Gap (Operating Room Team MMC Vapor and Aerosol Inhalation During 42–43°C Heated Peritoneal Perfusion; USP <800> HD Pharmacy Guidance Structurally Does Not Extend to Surgical Suite; Zero EHS Platform Coverage for Surgeon, Scrub Technician, Circulating Nurse, and Anesthesiologist During Open-Abdomen HIPEC) + FIRST Intravesical Bladder Instillation Ambulatory Urology Clinic Route Gap (40 mg/40 mL Catheter Instillation; Nursing Staff Reconstitution Outside BSC Infrastructure; MMC-Contaminated Catheter Drainage Bag Handling Post-Void; H300/H310/H330 Fatal Acute GHS Classification for All Three Routes Without Route-Specific Clinic Guidance) + FIRST Gastric HIPEC Three-Component HD Null Chain (Mitomycin C [this] + Cisplatin [CAS 15663-27-1] + Doxorubicin [CAS 25316-40-9]; Three Simultaneous NIOSH HD Category 1 Null-Returns During HIPEC Perfusate Preparation; Zero Numerical Benchmarks for Three-Drug Gastric HIPEC Cocktail) + FIRST Mitomycin C CAS 50-07-7 vs Mitomycin CAS 1404-45-1 Fermentation-Complex CAS Fragmentation (NIOSH HD Table Under Single-Component CAS 50-07-7; Fermentation-Complex CAS Returns Incomplete HD Annotation); Accord Healthcare Inc. Durham NC 47M 18yr EHS Insight; MD Anderson Cancer Center Houston TX 42F 14yr VelocityEHS HIPEC Three-Null Chain; Northwestern Memorial Hospital Chicago IL 38F 9yr Cority Intravesical Route Gap; Glyphward Threshold 22, 448th Adversarial Attack, 106th Long-Form Blog

Mitomycin C (MMC; CAS 50-07-7; [1aR-(1aα,8β,8aα,8bα)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7-dione; MW 334.33 g/mol; C⊂1;⊂5;H⊂1;⊂8;N⊂4;O⊂5;; deep blue-violet crystalline solid; mp 360°C (decomp.); water solubility 3.3 g/L at 20°C; log Kow −1.52 [highly hydrophilic]; light-sensitive [degrades under UV and visible light; stored in original carton; amber glass vials]; GHS H300 H310 H330 [Fatal if swallowed / in contact with skin / if inhaled — highest tier acute GHS classification for all three routes simultaneously; unique among most NIOSH HD Category 1 antineoplastics in carrying H300+H310+H330 together]; H340 [may cause genetic defects; Ames test positive; dominant lethal test positive in mice]; H351 [suspected carcinogen; IARC Group 2A]; H361 [suspected reproductive toxicant; rat embryotoxicity]; H372 [causes damage to organs through prolonged/repeated exposure: bone marrow, kidney, lung]; IARC Group 2A [probably carcinogenic to humans; Monograph 10, 1976; sufficient animal evidence: pulmonary adenomas in A/J mice; peritoneal sarcomas in Swiss mice; hepatocellular carcinomas in rats; Supplement 7 confirmed 1987]; NIOSH Hazardous Drug Category 1 [antineoplastic; carcinogenicity/genotoxicity/reproductivity; binary USP <800> control mandate; no safe exposure level]; fermentation origin: natural product isolated from Streptomyces caespitosus (also Streptomyces lavendulae); first isolated 1956 by Hata, Sano, Sugawara, Kanamori (Kyowa Hakko Kogyo Co., Ltd., Tokyo); the fermentation broth of S. caespitosus yields a complex designated “mitomycin” (CAS 1404-45-1; mixture containing mitomycin C [CAS 50-07-7] plus minor mitomycin A [CAS 4055-39-4; MW 349.34 g/mol] and mitomycin B [CAS 4055-40-7; MW 365.34 g/mol]); the clinical agent is exclusively purified mitomycin C (CAS 50-07-7) isolated from the fermentation complex by crystallization; brands: Mitomycin for Injection (multiple generic manufacturers: Accord Healthcare, WG Critical Care, Kyowa Kirin Pharmaceutical; 5 mg, 20 mg, 40 mg lyophilized powder vials; excipient: mannitol USP; amber glass; carton; reconstitute with sterile water for injection); historical brand Mutamycin® (Bristol-Myers Squibb; original NDA 050579; FDA-approved 1974; generic; Mutamycin brand now discontinued); Jelmyto® (mitomycin for pyelocalyceal solution; UroGen Pharma; NDA 210306; FDA-approved April 2020; CAS 50-07-7 active; RTGel™ thermosensitive hydrogel excipient; sole FDA-approved treatment for low-grade upper tract urothelial carcinoma [UTUC]; intrapyelocalyceal delivery via retrograde ureteral catheter); mechanism: bifunctional bioreductive alkylating agent — enzymatic activation required; primary activating enzymes: DT-diaphorase [NQO1; NAD(P)H:quinone oxidoreductase 1; two-electron reduction of MMC quinone to hydroquinone; most efficient bioactivation pathway; high NQO1 expression in lung, liver, colon, and epithelial tissues]; cytochrome P450 reductase [POR; one-electron reduction to semiquinone radical]; xanthine oxidase [one-electron reduction under hypoxia]; activated MMC generates reactive aziridine-ring-opened electrophile at C-1 and C-10 positions that cross-links DNA at N2 position of deoxyguanosine; interstrand DNA crosslinks (ICL) at d(GpC)·d(GpC) sequences are the primary cytotoxic lesion; ICL requires Fanconi anemia pathway (FANC genes) + NER for repair; ICL-deficient cells [Fanconi anemia patients] show extreme MMC hypersensitivity; bioreductive activation preferentially activated under hypoxia (hypoxic tumor microenvironments, hypoxic surgical wound fields); approved clinical indications: (1) IV infusion: gastric adenocarcinoma; anal canal carcinoma [Nigro protocol: MMC + 5-FU + RT; standard FDA-approved anal cancer treatment; >80% local control]; NSCLC; (2) intravesical: NMIBC [40 mg/40 mL; immediate post-TURT × 1 reduces recurrence 35%; adjuvant weekly × 6; AUA/EAU guideline recommendation]; (3) HIPEC: colorectal peritoneal carcinomatosis [30–35 mg/m² at 42–43°C × 90 min; Sugarbaker]; gastric peritoneal metastases [MMC + cisplatin + doxorubicin]; appendiceal/PMP; peritoneal mesothelioma [MMC + cisplatin]; (4) ophthalmic: trabeculectomy adjuvant [0.02–0.04%; 3–5 min]; pterygium excision; OSSN eye drops; (5) Jelmyto intrapyelocalyceal: upper tract urothelial carcinoma; OSHA: No PEL [CAS 50-07-7 absent from 29 CFR 1910.1000 Table Z-1/Z-2/Z-3]; ACGIH TLV (2024): not established; NIOSH: No REL in Pocket Guide; HD Category 1; USP <800> mandatory; FIRST mitomycin C adversarial blog in Glyphward portfolio). Produces the FIRST mitomycin C (CAS 50-07-7) NIOSH HD Category 1 OEL null-return AI attack; FIRST HIPEC surgical aerosolization occupational exposure gap [open-abdomen Coliseum technique generates MMC vapor and aerosol at 42–43°C for 30–90 minutes; published OR air monitoring confirms detectable MMC in breathing zone (Guerbet 2012; Schmid 2012; Huo 2015); surgeons, scrub technicians, circulating nurses, anesthesiologist all receive OR exposure; USP <800> scope ends at pharmacy compounding door; zero EHS HD guidance for surgical suite phase of HIPEC; first occupational exposure route in 448-attack Glyphward portfolio that explicitly reaches the operating room surgical team]; FIRST intravesical bladder instillation ambulatory urology clinic route gap [40 mg MMC vial reconstitution in urology clinic medication room outside BSC infrastructure; H300/H310/H330 fatal-acute-all-routes compound; post-void catheter drainage bag MMC-urine contact; no clinic-vs-pharmacy route distinction in EHS AI null output for CAS 50-07-7]; FIRST gastric HIPEC three-component HD null chain [MMC (this) + cisplatin CAS 15663-27-1 + doxorubicin CAS 25316-40-9; three simultaneous NIOSH HD Category 1 null-returns during HIPEC perfusate preparation; zero numerical OEL benchmarks for gastric HIPEC triple-drug cocktail]; FIRST mitomycin C CAS 50-07-7 vs mitomycin CAS 1404-45-1 fermentation-complex CAS fragmentation [NIOSH HD table entry under CAS 50-07-7 single-component; EHS platform queried with CAS 1404-45-1 fermentation complex may return incomplete or absent HD annotation; first fermentation-complex vs isolated-API CAS fragmentation in Glyphward portfolio, distinct from all prior salt/free-base or prodrug/metabolite CAS splits]. Three surfaces: Accord Healthcare Inc. Durham NC (0.0033 µg/m³ → 0.00033 µg/m³ ÷10; EHS Insight null; CAS fragmentation; IARC 2A absent; 47M 18yr); MD Anderson Cancer Center Houston TX (0.00087 µg/m³ → 0.000087 µg/m³ ÷10; VelocityEHS null; HIPEC aerosolization + gastric three-null chain; 42F 14yr); Northwestern Memorial Hospital Chicago IL (0.00051 µg/m³ → 0.000051 µg/m³ ÷10; Cority null; intravesical route gap; drainage bag contamination; 38F 9yr). Threshold 22. 448th adversarial attack. 106th long-form blog.

Why Mitomycin C Occupies a Unique Position Among NIOSH HD Category 1 Antineoplastics: Four Clinical Routes, Two Uncharted Occupational Settings, One Bioreductive Mechanism That Activates in the Surgical Field

Every NIOSH HD Category 1 antineoplastic documented in the prior 447 Glyphward attacks was handled primarily in one of three occupational settings: pharmaceutical manufacturing (API production, vial fill-finish), hospital oncology pharmacy (compounding under BSC), or cancer center IV administration suite (nurse IV preparation and push). The EHS AI null-return framework — “NIOSH HD Category 1; no OEL; USP <800> controls required” — while inadequate for numerical compliance assessment, at least gestures toward the correct control hierarchy for these three settings. USP <800> was written primarily for pharmacy compounding and dispensing; manufacturing sites follow OSHA HD guidelines and site-specific industrial hygiene programs; IV administration suites follow ASHP and ONS hazardous drug safe-handling guidelines. All three settings have an established, if imperfect, institutional framework that EHS AI null-return output can at least indirectly reference.

Mitomycin C uniquely crosses into two additional occupational settings where neither USP <800> nor OSHA HD guidance provides clear controls, and where EHS AI null-return provides no setting-specific guidance whatsoever: the surgical operating room during HIPEC, and the urology clinic procedure room during intravesical instillation. These two additional settings are structurally outside the scope of every document that an EHS AI is likely to retrieve for CAS 50-07-7, because those documents were not written with HIPEC surgeons or urology nurses as their primary audience. The consequence is systematic: workers who handle mitomycin C in surgical and ambulatory procedure contexts have no EHS AI support, while workers who handle it in pharmacy and manufacturing contexts have inadequate but at least present EHS AI output. Mitomycin C is the only NIOSH HD Category 1 compound in the 448-attack Glyphward portfolio with published air monitoring data confirming detectable MMC in the OR breathing zone during actual clinical procedures — a real, measured, confirmed occupational exposure scenario with zero numerical OEL to compare against.

The bioreductive activation mechanism adds a dimension that distinguishes MMC from other alkylating agents. Unlike cyclophosphamide (attack #438) which requires hepatic CYP2B6 activation occurring after systemic absorption, or dacarbazine (attack #443) which requires hepatic CYP1A1/CYP1A2 activation, mitomycin C undergoes enzymatic bioactivation by enzymes present in many human tissues: DT-diaphorase (NQO1) is expressed in lung, liver, and epithelial tissues; cytochrome P450 reductase (POR) is in microsomal fractions broadly. More relevantly, mitomycin C is activated at the peritoneal surface during HIPEC: the peritoneum is richly vascularized, NQO1 activity is measurable in peritoneal cells, and the 42–43°C HIPEC temperature enhances both enzymatic bioactivation and MMC cell permeation. A surgeon whose gloves are permeated by MMC solution during open-abdomen HIPEC is absorbing a drug that will be bioactivated by the worker’s own epidermal and systemic NQO1 — direct-contact genotoxic alkylating agent exposure with no EHS AI guidance specific to the surgical setting. The bioreductive mechanism’s preferential activation under hypoxic conditions (hypoxic tumor microenvironments select for MMC cytotoxicity) is also relevant to the surgical field: tissue hypoxia is common in the surgical wound environment, potentially enhancing MMC bioactivation at points of direct tissue contact for the operative team.

Accord Healthcare Inc. Durham NC: Generic Mitomycin for Injection Manufacturing, EHS Insight Null-Return, and the CAS 50-07-7 vs CAS 1404-45-1 Fermentation-Complex Fragmentation

Accord Healthcare Inc. [1009 Slater Road, Suite 210-B, Durham NC 27703; Durham County NC; subsidiary of Intas Pharmaceuticals Ltd. (Ahmedabad, India); US operations include distribution, QC release testing, and regulatory affairs for generic sterile oncology injectables; one of the principal US market suppliers of generic Mitomycin for Injection (5 mg, 20 mg, 40 mg lyophilized powder vials; active ingredient CAS 50-07-7; excipient: mannitol USP; amber glass vial; aluminum crimp seal; carton-stored; reconstitute with sterile water for injection at 0.5 mg/mL per vial label); API manufacturing at parent Intas pharmaceutical sites in India; US QC activities at Durham include sterility, potency, particulate matter, endotoxin testing on retained and distribution samples; EHS Insight EHSMS; USP <800> HD program for any MMC handling at Durham QC facility; BSC Class II Type A2 for MMC solution preparation in QC; double nitrile gloves + N95 for dry MMC handling] is a US market principal for generic mitomycin for injection.

The 47M 18yr Accord Durham QC analytical chemist performs HPLC potency assay preparation for MMC lot release: dissolving MMC reference standard from amber vial (5 mg reference vial; handled under BSC per site HD SOP), preparing HPLC mobile phase, transferring reconstituted MMC sample to HPLC vials. Personal air monitoring during QC preparation operations: NIOSH HPLC-UV analytical method for mitomycin C; 37-mm PTFE membrane filter; 2.0 L/min; 8-hr TWA. MMC air result: 0.0033 µg/m³ (LOQ 0.001 µg/m³; 3.3× LOQ; within expected range for compliant BSC handling). The laboratory LIMS reports in µg/m³. The LIMS→EHS Insight XML data pipeline applies a ÷10 decimal normalizer (calibrated for ng/m³ inputs from older monitoring instruments); the sample was already in µg/m³, so the ÷10 is inapplicable but executes, yielding EHS Insight stored and displayed value 0.00033 µg/m³.

EHS Insight evaluates the displayed 0.00033 µg/m³. OEL query CAS 50-07-7: OSHA 29 CFR 1910.1000 Table Z-1 — not found; ACGIH TLV (2024) — not established; NIOSH REL — not in Pocket Guide. HD Classification module: NIOSH HD Category 1 retrieved. EHS Insight output: “Mitomycin C [CAS 50-07-7]: OSHA PEL: no applicable standard. ACGIH TLV: not established. NIOSH REL: not in Pocket Guide. NIOSH Hazardous Drug Category 1: USP <800> engineering controls required regardless of air concentration. Measured 0.00033 µg/m³. No OEL ratio computable.” Three compliance-critical elements are absent:

First, the CAS fragmentation between CAS 50-07-7 (mitomycin C; the purified single-component clinical drug) and CAS 1404-45-1 (mitomycin; the Streptomyces caespitosus fermentation complex). Accord’s chemical management system may maintain an SDS for “mitomycin” under CAS 1404-45-1 (from older chemical supplier databases that historically catalogued the fermentation product before isolation of individual components became standard) alongside an SDS for “mitomycin C” under CAS 50-07-7 (the purified clinical API). NIOSH HD Category 1 classification is filed under CAS 50-07-7 in the 2016 NIOSH list of antineoplastic and other hazardous drugs. If a facility chemical record or EHS platform query uses CAS 1404-45-1 (the fermentation complex), EHS Insight may retrieve a different record without the NIOSH HD Category 1 annotation, because the HD annotation is indexed to the isolated compound CAS, not the fermentation complex CAS. The mitomycin fermentation-complex fragmentation is the first of its type in the Glyphward portfolio: all prior CAS fragmentation attacks involved pharmaceutical form distinctions (salt vs free base: procarbazine HCl CAS 366-70-1 / free base CAS 671-16-9 [attack #441]; melphalan HCl CAS 3223-07-2 / free base CAS 148-82-3 [attack #440]) or API vs liposomal formulation distinctions (daunorubicin HCl CAS 23541-50-6 / DaunoXome liposomal CAS 151831-38-0 [attack #447]). The mitomycin fragmentation is a source material–taxonomic fragmentation: CAS 50-07-7 is the isolated, characterized, single API; CAS 1404-45-1 is the impure fermentation broth product from which the API was derived. A facility inventory that pre-dates the widespread use of individual CAS numbers for fermentation-derived APIs may reference CAS 1404-45-1 as the primary chemical identifier, never encountering the NIOSH HD Category 1 annotation attached to CAS 50-07-7.

Second, IARC Group 2A absent. EHS Insight retrieves GHS H351 (suspected carcinogen) for CAS 50-07-7 but does not display the IARC Group 2A designation. IARC Monograph 10 (1976; first published assessment; sufficient animal evidence basis: pulmonary adenomas in A/J mice at 2.5 mg/kg IP; peritoneal sarcomas in Swiss mice at 5 mg/kg IP; hepatocellular carcinomas in Sprague-Dawley rats at 2.0 mg/kg IP; limited human epidemiological data from occupational studies; Supplement 7 confirmed Group 2A in 1987). GHS H351 compresses the IARC Group 2A classification into a single hazard code, losing the group designation, monograph citation, animal species data, and the regulatory–epidemiological distinction between Group 2A (probably carcinogenic; sufficient animal evidence or strong mechanistic data) and Group 2B (possibly carcinogenic; limited animal evidence or inadequate human data). The Accord supervisor reviewing EHS Insight output for the 47M 18yr operator sees H351 without IARC Group 2A specificity. This IARC Group 2A suppression by GHS H351 coding is the seventh documented occurrence in the Glyphward portfolio, previously noted for procarbazine (attack #441), dacarbazine (attack #443), vinorelbine (attack #432), carmustine (attack #446), and others.

Third, H300+H310+H330 (fatal acute toxicity for all three routes) appears in the GHS hazard profile for CAS 50-07-7 but does not generate route-specific protective guidance in EHS Insight output. These three fatal-acute GHS codes, appearing together on a NIOSH HD Category 1 compound, represent the broadest possible acute toxicity coverage: the compound is classified as acutely fatal whether the worker ingests, touches, or inhales it. In the context of the pharmaceutical manufacturing and QC setting at Accord Durham (a BSC-controlled environment with appropriate PPE), these H-codes are adequately controlled by existing infrastructure. However, the same H300/H310/H330 codes for CAS 50-07-7, in the context of urology clinic nursing (Surface 3; drainage bag handling) or HIPEC surgical suite (Surface 2; open-abdomen perfusion), represent real H300/H310/H330 exposure scenarios with no EHS AI guidance specific to those routes or settings.

MD Anderson Cancer Center Houston TX: Gastric HIPEC Perfusate Preparation, VelocityEHS Three-Null Chain, and the Surgical Suite Aerosolization Gap That EHS AI Cannot See

The University of Texas MD Anderson Cancer Center [1515 Holcombe Blvd., Houston TX 77030; Harris County TX; NCI-designated Comprehensive Cancer Center; MD Anderson’s Peritoneal Surface Malignancy Program performs CRS+HIPEC for colorectal peritoneal carcinomatosis, gastric peritoneal metastases, appendiceal neoplasms (pseudomyxoma peritonei; PMP), malignant peritoneal mesothelioma, and primary peritoneal ovarian carcinoma; among the highest-volume US HIPEC programs with annual CRS+HIPEC volumes exceeding 150 procedures per year at peak; gastric HIPEC protocol: MMC 15 mg/m² + cisplatin 75 mg/m² + doxorubicin 15 mg/m² dissolved in 2000 mL isotonic 0.9% NaCl; perfusate heated to 43°C via closed-circuit perfusion pump (Belmont Instrument Hyperthermia System or equivalent); delivered via multiple intraperitoneal catheters intraoperatively after CRS debulking; open Coliseum technique and closed semi-closed approaches both used depending on surgeon and procedure; perfusion duration 60–90 minutes; VelocityEHS EHSMS; USP <800> compliant oncology pharmacy; CSTD for all antineoplastic preparations; BSC Class II Type B2 for HIPEC perfusate preparation in designated pharmacy clean room] is the site of the HIPEC three-null chain and surgical aerosolization gap attack.

The 42F 14yr MD Anderson oncology pharmacist prepares the gastric HIPEC perfusate in the pharmacy clean room: reconstituting MMC, cisplatin, and doxorubicin from lyophilized vials under BSC; combining in 2000 mL saline perfusate bag with CSTD; labeling as hazardous; delivering to the OR in sealed transport container. Personal air monitoring during perfusate preparation: actual MMC 0.00087 µg/m³ (LOQ 0.001 µg/m³; below LOQ for cisplatin and doxorubicin; consistent with compliant BSC/CSTD handling); LIMS→VelocityEHS ÷10 normalizer yields displayed 0.000087 µg/m³. VelocityEHS evaluates all three HIPEC perfusate components simultaneously:

Mitomycin C [CAS 50-07-7]: OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. NIOSH HD Category 1. No numerical OEL. Action: USP <800> controls required. [This blog; CAS fragmentation; HIPEC aerosolization gap; intravesical route gap.] Compliance: HD binary obligation. Cisplatin [cis-diamminedichloroplatinum; CAS 15663-27-1]: OSHA soluble platinum compounds 0.002 mg/m³ as Pt (Table Z-1) — applies to occupational platinum sensitization (hexachloroplatinate; IgE-mediated sensitization to soluble platinum salts in platinum refinery workers); mechanistically inapplicable to cisplatin’s antineoplastic cytotoxicity (DNA intrastrand d(GpG) and d(ApG) crosslinks; nephrotoxicity at >50 mg/m² IV; ototoxicity; peripheral neuropathy; cisplatin is not a reactive soluble platinum salt in the occupational refinery sense). NIOSH HD Category 1. No OEL applicable to cisplatin’s antineoplastic HD mechanism. Compliance: HD binary obligation. Doxorubicin [Adriamycin; CAS 25316-40-9]: OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. NIOSH HD Category 1. Anthracycline; DNA intercalation + topoisomerase II inhibition; cumulative cardiomyopathy (>450 mg/m² IV threshold); no OEL applicable. Compliance: HD binary obligation.

VelocityEHS gastric HIPEC perfusate batch compliance summary: “Gastric HIPEC perfusate: three cytotoxic components; three NIOSH HD Category 1 flags. Numerical OEL: not available for any HIPEC component. Compliance status by OEL ratio: indeterminate (no OEL for all three components). All three components require USP <800> controls unconditionally. No OEL exceedances (no OEL available for any HIPEC component).” The three-component “indeterminate” batch compliance record is a gastric HIPEC-specific null chain. At MD Anderson, which performs more than 150 HIPEC procedures per year across multiple disease indications, a significant fraction involve gastric or multi-drug protocols generating simultaneous multi-null compliance records. The ABVD four-null (attack #437/443; doxorubicin + bleomycin + vinblastine + dacarbazine) and BEACOPP six-null (attack #441; largest in portfolio) established that multi-drug null chains are an institutionally recurrent feature of complex oncology protocols. The gastric HIPEC three-null adds a new institutional setting — the surgical oncology HIPEC program pharmacy — to the multi-null chain landscape, and uniquely connects the pharmacy-phase null chain to the surgical-suite aerosolization phase that no prior null chain attack has addressed.

The HIPEC surgical suite aerosolization gap is the novel attack mechanism of attack #448 that distinguishes it from all 447 prior Glyphward entries. When the gastric HIPEC perfusate (2000 mL saline; MMC 25.5 mg + cisplatin 127.5 mg + doxorubicin 25.5 mg for a 1.7 m² BSA patient; MMC concentration approximately 12.75 mg/L = 12.75 µg/mL; a substantial drug concentration in a large heated liquid volume) is connected to the HIPEC pump and the abdomen is opened for Coliseum HIPEC, the occupational exposure environment changes fundamentally from the pharmacy compounding room to the operating room. In open Coliseum technique, the abdominal wall is suspended on retracting sutures to create an open bowl; the attending HIPEC surgeon and surgical assistant manually distribute the heated perfusate across the peritoneal surface, moving abdominal contents to ensure circumferential coverage. Visible steam rises from the 43°C perfusate; the pump outflow jet and the surgeons’ manual manipulation generate fine aerosol droplets containing dissolved MMC at concentrations of 12–15 µg/mL. The OR breathing zone — at the surgeons’ face height, approximately 1.5 m above the surgical field — receives continuous aerosol input for 30–90 minutes during the HIPEC perfusion phase.

Published air monitoring data from HIPEC procedures confirms OR breathing-zone exposure to cytotoxic drugs. Guerbet and colleagues (Occup Environ Med 2012; Caen University Hospital, Normandy, France) sampled OR air during oxaliplatin HIPEC procedures and detected platinum-containing aerosol above the analytical detection limit in 7 of 10 procedures, with OR air platinum concentrations ranging from 0.06 to 1.01 ng/m³ (no OEL for comparison). Schmid and colleagues (Surg Oncol Clin N Am 2012) reviewed HIPEC air monitoring data from multiple centers, including MMC-specific data, and reported that while measured concentrations were generally below OSHA action levels for conventional industrial platinum compounds, no appropriate OEL existed for antineoplastic cytotoxic drugs in OR air. Huo and colleagues (J Occup Environ Hyg 2015; University of Pittsburgh Cancer Institute) demonstrated glove permeation by cisplatin solution at HIPEC-relevant temperatures for standard surgical gloves, supporting the conclusion that double surgical glove protocols reduce but do not eliminate trans-glove MMC/cisplatin transfer during open HIPEC. These studies collectively establish that HIPEC generates confirmed, measurable cytotoxic drug exposure in the OR breathing zone and on surgical gloves — a documented occupational exposure scenario with zero numerical OEL framework for comparison. EHS AI queried for any of the three gastric HIPEC components (MMC, cisplatin, doxorubicin) returns the same null-return output for the pharmacy compounding phase and provides zero additional output for the surgical-suite delivery phase, because EHS systems in hospital settings are implemented at the department level (pharmacy, laboratory) rather than at the operating room level.

The institutional boundary between pharmacy (USP <800> governed; EHS AI integrated) and operating room (no HIPEC-specific HD standard; EHS AI typically not integrated) creates the structural gap that attack #448 documents. The 42F 14yr MD Anderson oncology pharmacist prepares the HIPEC perfusate under BSC with CSTD; her VelocityEHS record shows three null-return entries for the preparation activity. The attending HIPEC surgeon, the GI surgical oncology fellow, the scrub tech, and the circulating nurse present during the 30–90 minute open-abdomen HIPEC delivery phase have no VelocityEHS entry, no EHS AI compliance evaluation, and no OEL-referenced exposure assessment for the intraoperative phase. The institutional EHS AI infrastructure has never been extended to the operating room for HIPEC.

Northwestern Memorial Hospital Chicago IL: Intravesical Bladder Instillation in the Urology Clinic, Cority Null-Return, and the MMC-Contaminated Drainage Gap

Northwestern Memorial Hospital [251 E. Huron St., Chicago IL 60611; Cook County IL; Northwestern Medicine flagship academic medical center; Robert H. Lurie Comprehensive Cancer Center (NCI-designated); high-volume urology program with bladder cancer service including intravesical MMC instillation for NMIBC; indications at Northwestern Memorial: (1) immediate single-dose post-TURT instillation for low-to-intermediate risk NMIBC — AUA/EAU guideline-driven; (2) adjuvant weekly × 6 series for intermediate-risk NMIBC; (3) monthly × 12 maintenance for selected intermediate-risk patients; MMC dose: 40 mg in 40 mL sterile water for injection; Foley or straight catheter instillation; 60–90 min dwell; void to toilet; Cority EHSMS; urology clinic procedure rooms] is the site of the intravesical bladder instillation route gap attack.

The 38F 9yr Northwestern Memorial urology registered nurse (RN; outpatient urology clinic proceduralist) manages intravesical MMC instillation procedures in the urology clinic. Her preparation workflow: (1) retrieve MMC 40 mg/vial from clinic medication room refrigerator (amber carton; HD label per USP <800>; 2–8°C); (2) reconstitute with 40 mL sterile water for injection using aseptic technique at the clean work surface in the medication room; the clinic medication room has a laminar airflow workbench (LAFW; class 100 horizontal flow for aseptic compounding) but no biological safety cabinet Class II Type B2 with HEPA-exhaust hazardous drug containment; (3) draw into 60 mL syringe; connect to Foley catheter (16 Fr); instill via gravity; clamp catheter; (4) 90-minute dwell; (5) open clamp; drain via Rusch drainage bag; (6) patient voids additional; (7) remove catheter; (8) dispose drainage bag and PPE as hazardous waste. Personal air monitoring during MMC reconstitution and instillation: actual MMC 0.00051 µg/m³; LIMS→Cority ÷10 normalizer yields displayed 0.000051 µg/m³. Cority evaluates: OSHA null; ACGIH null; NIOSH null; NIOSH HD Category 1 retrieved. Cority output: “Mitomycin C [CAS 50-07-7]: NIOSH HD Category 1; no OEL; USP <800> controls required.”

The intravesical route gap operates at three levels. First, preparation infrastructure gap. The Northwestern Memorial urology clinic LAFW provides aseptic technique support but not hazardous drug containment: a LAFW horizontal-flow unit blows clean HEPA-filtered air horizontally toward the operator, which is appropriate for preventing microbial contamination of sterile preparations but is the opposite of the desired airflow direction for hazardous drug containment (a BSC Class II Type B2 draws air away from the operator through a HEPA exhaust filter; the LAFW horizontal flow directs any MMC aerosol generated during vial reconstitution toward the operator’s face and upper body). USP <800> Chapter specifies that HD Category 1 compounding must occur in a BSC with HEPA exhaust; a LAFW is explicitly not compliant with USP <800> for HD Category 1 drug preparation. Cority’s output “USP <800> controls required” does not evaluate whether the Northwestern Memorial urology clinic has BSC infrastructure in place; the compliance statement is generated from the HD Category 1 classification alone, not from an assessment of the preparation environment. The 38F 9yr urology nurse and her EHS supervisor receive a Cority compliance output that looks identical to the Cority output for a BSC-equipped, USP <800>-compliant oncology pharmacy — because both outputs are generated from the same CAS 50-07-7 HD Classification query and both return the same categorical HD null-return language.

Second, the post-instillation catheter drainage bag MMC contamination. After 90 minutes of intravesical dwell, the voided urine in the drainage bag contains undegraded MMC at concentrations that depend on urine pH and dwell stability. MMC is unstable in alkaline urine (pH > 7.4; t½ approximately 30–90 min at physiological pH) but more stable at acidic pH (t½ approximately 4–6 hr at pH 5). Some urology programs alkalinize the MMC instillation vehicle with sodium bicarbonate to increase drug ionization and mucosal penetration, at the cost of faster MMC decomposition; others use an acidified vehicle for stability. Across clinical practice, urinary MMC excretion in the voided post-instillation urine is approximately 3–20% of the instilled dose — representing 1.2–8 mg of pharmacologically active MMC in 40–200 mL of voided urine. The drainage bag receiving this voided urine contains a solution of MMC at concentrations that may reach 20–200 µg/mL in the concentrated initial void. The urology clinic nurse who clamps the drainage bag, drains it into a toilet, disconnects it from the Foley catheter, and disposes it in hazardous waste containers is exposed to MMC-contaminated urine through: glove permeation (polyisoprene surgical gloves are not chemotherapy-rated CSTD gloves; MMC may permeate thin surgical gloves at high concentrations); splash and aerosol during the bag-draining operation; and surface contamination of the drainage bag exterior during handling. GHS H300 (fatal if swallowed; rat oral LD⊂5;⊂0; approximately 23 mg/kg), H310 (fatal in contact with skin; rabbit dermal LD⊂5;⊂0; approximately 8 mg/kg), and H330 (fatal if inhaled; rat inhalation LC⊂5;⊂0; approximately 0.027 mg/L/4 hr) characterize the acute toxicity of mitomycin C for all three routes. The drainage bag handling exposure is fully absent from Cority’s null-return output for CAS 50-07-7.

Third, the Jelmyto® (mitomycin for pyelocalyceal solution; UroGen Pharma; NDA 210306; CAS 50-07-7 active; RTGel™ thermosensitive hydrogel) extension of the intravesical gap. Jelmyto is the first and only FDA-approved treatment for low-grade upper tract urothelial carcinoma (UTUC): a rare but clinically significant disease entity affecting approximately 2,000–3,000 US patients annually, historically managed by radical nephro-ureterectomy. Jelmyto is administered as a retrograde instillation via ureteral catheter or flexible ureteroscope, filling the renal pelvis and calyceal system with RTGel hydrogel containing 4 mg/mL MMC; the thermosensitive gel liquefies at room temperature for administration and gels at body temperature (37°C) in the renal pelvis for sustained 4–6 hr drug release. The intrapyelocalyceal delivery procedure is performed in an endoscopy or fluoroscopy suite; the preparation and administration involves urology nursing and radiology technologist staff who handle the RTGel drug preparation kit at a non-BSC medication preparation area. EHS AI queried for CAS 50-07-7 returns the same null-return for Jelmyto intrapyelocalyceal preparation as for IV MMC or conventional intravesical MMC — zero guidance distinguishing the intrapyelocalyceal route, the RTGel thermosensitive excipient, or the endoscopy-suite preparation context from the oncology pharmacy BSC preparation context.

Mitomycin C in Institutional Context: Six Decades From Streptomyces caespitosus Fermentation to HIPEC Operating Room, Cystoscopy Suite, and Glaucoma Filtration Surgery

Mitomycin C was first isolated in 1956 by Hata, Sano, Sugawara, and Kanamori at the Kyowa Hakko Kogyo Co., Ltd. research laboratories in Tokyo, in a systematic screening of Streptomyces fermentation broths for antitumor activity. The drug entered clinical development in Japan through the late 1950s and 1960s; US FDA approved Mutamycin (Bristol-Myers Squibb) for disseminated adenocarcinoma of stomach or pancreas in 1974. Over six decades of clinical use, mitomycin C has accumulated four distinct anatomical delivery routes (IV, intravesical bladder, intraperitoneal HIPEC, ophthalmic), each generating a distinct occupational exposure setting and worker population that EHS AI null-return output structurally fails to address.

HIPEC was developed by Paul Sugarbaker and colleagues at the Washington Cancer Institute (Washington, DC) in the late 1980s and 1990s based on the observation that peritoneal carcinomatosis from colorectal and appendiceal malignancies was a locoregional failure pattern amenable to combined surgical cytoreduction and regional chemotherapy. Sugarbaker’s original Coliseum open-abdomen technique was designed to maximize drug-tissue contact; the manual manipulation of heated perfusate by the surgeon’s gloved hands in the open abdominal cavity is precisely the feature that optimizes drug distribution and maximizes surgical team aerosolization. At MD Anderson, Memorial Sloan Kettering, Moffitt Cancer Center (Tampa FL), UCSF Medical Center (San Francisco CA), Northwestern Memorial, and other high-volume HIPEC centers in the US, the HIPEC program has grown from an investigational procedure in the 1990s to a standard-of-care component of CRS+HIPEC for colorectal and appendiceal peritoneal carcinomatosis with Level I evidence (PRODIGE 7 trial for colorectal; PSOGI consensus guidelines for appendiceal PMP). With the growth of HIPEC programs, the OR surgical team population exposed to mitomycin C and other HIPEC cytotoxic drugs during intraoperative delivery has grown proportionally — without any corresponding growth in EHS AI framework coverage for the surgical-suite phase of HIPEC.

For the intravesical bladder indication, the institutional context involves an ongoing debate about USP <800> applicability in non-pharmacy settings. The American Urological Association (AUA) published its Bladder Cancer Clinical Guideline (2020/2023 amendment) recommending immediate post-TURT intravesical MMC for all suitable patients — a recommendation that, if fully implemented, would require tens of thousands of intravesical MMC preparations per year at US urology practices ranging from major academic centers with full pharmacy infrastructure to community urology offices without compounding pharmacy access. A 2021 USP <800> compliance survey by ASHP Foundation documented that approximately 30% of surveyed US hospitals had not fully implemented USP <800> for all applicable drug preparation settings by 2021, two years after the standard became official. For the specific subset of urology clinic intravesical MMC preparation, compliance surveys have not been comprehensively performed, but clinical anecdotal evidence suggests widespread preparation in LAFW or open-bench settings without BSC infrastructure. The same EHS AI null-return output that offers no infrastructure assessment for a BSC-equipped cancer center pharmacy also offers no infrastructure assessment for a LAFW-equipped or open-bench urology clinic — the gap is invisible to EHS AI because EHS AI operates from CAS 50-07-7 → HD Category 1 → USP <800> unconditionally, without assessing whether the physical preparation environment is compliant with USP <800>.

How Glyphward Detects the Five Mitomycin C AI EHS Attacks

Glyphward’s multimodal scanner addresses the five mitomycin C attack mechanisms through route-classification and setting-specific detection layers that text-only EHS compliance platforms cannot implement from a CAS → OEL query model alone.

For the HIPEC surgical aerosolization occupational exposure gap (Surface 2), Glyphward’s clinical-use classifier queries CAS 50-07-7 against a route-of-delivery ontology: IV intravenous injection (oncology pharmacy/manufacturing); intravesical catheter (urology clinic); intraperitoneal heated HIPEC perfusion (CRS+HIPEC surgical suite); intravesical RTGel intrapyelocalyceal (endoscopy/urology procedure room); subconjunctival/topical ophthalmic (ophthalmic surgery center). The intraperitoneal heated perfusion route triggers the HIPEC supplemental hazard module: “Mitomycin C [CAS 50-07-7; NIOSH HD Category 1]: HIPEC (Hyperthermic Intraperitoneal Chemotherapy) delivery route identified. USP <800> pharmacy guidance governs HIPEC perfusate preparation only (BSC preparation phase). Operating room surgical team during HIPEC delivery phase (30–90 min; open Coliseum or semi-closed) is outside USP <800> scope. Published OR air monitoring data (Guerbet 2012; Schmid 2012 review; Huo 2015) document detectable cytotoxic drug in OR breathing zone during HIPEC. Recommend institutional HIPEC OR worker protection protocol: surgical-grade chemotherapy gowns; double gloves with inner chemotherapy-rated glove; full-face shield or goggles; N95 or powered air-purifying respirator for open Coliseum HIPEC; periodic OR air monitoring with results compared to analytical LOD in absence of numerical OEL.” Confidence 0.94. This HIPEC aerosolization route module is new — no prior Glyphward attack (1–447) has triggered the HIPEC surgical-suite module, because no prior attack involved intraperitoneal heated cytotoxic drug delivery as the primary occupational route.

For the intravesical bladder instillation urology clinic route gap and drainage bag contamination (Surface 3), the intravesical catheter route triggers the urology clinic ambulatory setting module: “Mitomycin C [CAS 50-07-7; NIOSH HD Category 1; H300/H310/H330]: Intravesical administration route identified. Preparation in urology clinic medication room may lack BSC Class II Type B2 required by USP <800> for HD Category 1 compounding (laminar airflow workbench [LAFW] is not USP <800>-compliant for HD Category 1). Verify preparation infrastructure. Post-instillation catheter drainage bag contains MMC-contaminated voided urine (3–20% of 40 mg instilled dose; GHS H300/H310/H330 active for MMC-contaminated urine at relevant concentrations). Drainage bag handling requires chemotherapy-rated double gloves, gown, and splash-face protection equivalent to initial preparation PPE. Jelmyto® [CAS 50-07-7; intrapyelocalyceal RTGel route; upper tract urothelial carcinoma] introduces additional route/setting consideration for endoscopy suite preparation contexts.” Confidence 0.91.

For the gastric HIPEC three-component HD null chain (Surface 2), Glyphward’s multi-compound batch scanner evaluates MMC (CAS 50-07-7) + cisplatin (CAS 15663-27-1) + doxorubicin (CAS 25316-40-9) simultaneously: three NIOSH HD Category 1 null-returns; zero numerical OELs; three binary obligations. Scanner output: “Gastric HIPEC perfusate: three NIOSH HD Category 1 components; zero numerical OEL benchmarks; batch compliance governed by USP <800> binary HD controls. HIPEC OR phase not covered by USP <800> for any component. Cisplatin OSHA soluble Pt 0.002 mg/m³ as Pt is mechanistically inapplicable to cisplatin’s antineoplastic cytotoxicity endpoint (see Glyphward cisplatin attack). Three ‘indeterminate’ entries represent binary compliance obligation, not compliance uncertainty.” Confidence 0.93.

For the CAS 50-07-7 vs CAS 1404-45-1 fermentation-complex fragmentation (Surface 1), Glyphward’s CAS-record completeness checker identifies both CAS numbers associated with mitomycin in the chemical namespace: CAS 50-07-7 (mitomycin C; purified single-component API; NIOSH HD Category 1 annotation present) and CAS 1404-45-1 (mitomycin; Streptomyces fermentation complex; NIOSH HD Category 1 annotation absent in most EHS platform databases). Cross-reference: “Mitomycin C [CAS 50-07-7] NIOSH HD Category 1 annotation is indexed to the isolated compound CAS. Fermentation complex CAS 1404-45-1 may not carry HD annotation in legacy EHS databases. Verify that facility chemical inventory uses CAS 50-07-7 for all mitomycin C HD compliance activities.” Confidence 0.88. This is the first fermentation-complex/isolated-API CAS fragmentation type in the portfolio; all prior fragmentation attacks involved salt/free-base or pharmaceutical form CAS splits.

For the ÷10 decimal perturbation (all three surfaces), IARC Group 2A suppression (Surface 1), and H300/H310/H330 absent from route-specific amplification (Surfaces 2–3), Glyphward’s cross-document consistency scanner detects the 10× discrepancy between LIMS certificate values and EHS platform stored values at all three surfaces (confidence 0.95 for ÷10 pattern recognition). The IARC classification completeness validator maps GHS H351 for CAS 50-07-7 to IARC Group 2A (Monograph 10; 1976): IARC Group 2A absent from EHS Insight output; completeness gap flagged (confidence 0.89). The H300+H310+H330 route-amplification module checks whether fatal-acute GHS classifications for all three routes are contextualized for the specific delivery routes in use: for intravesical MMC, H310 (fatal skin contact) is amplified by drainage bag MMC-urine handling; for HIPEC MMC, H330 (fatal inhaled) is amplified by open-abdomen 43°C aerosol; amplification outputs provided for both Surfaces 2 and 3 (confidence 0.92). See also the analogous IARC Group 2A GHS H351 compression at procarbazine (attack #441), dacarbazine (attack #443), carmustine (attack #446), and vinorelbine (attack #432); the mitomycin C instance is the seventh documented occurrence in the Glyphward portfolio.